Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update

Core Insights - Lantheus Holdings, Inc. reported third quarter 2025 financial results, highlighting a slight increase in worldwide revenue but significant declines in net income and earnings per share [3][7][8] - The company is focusing on the commercial execution of its prostate cancer franchise, particularly PYLARIFY, while also advancing its strategic diversification plan [2][5] Financial Performance - Worldwide revenue for Q3 2025 was $384.0 million, a 1.4% increase from $378.7 million in Q3 2024 [3][21] - GAAP net income decreased by 78.8% to $27.8 million compared to $131.1 million in the prior year [3][8] - GAAP fully diluted earnings per share fell by 77.1% to $0.41 from $1.79 in Q3 2024 [3][8] - Adjusted net income (non-GAAP) was $85.7 million, down 30.9% from $124.1 million in the previous year [3][8] - Adjusted fully diluted earnings per share (non-GAAP) decreased by 25.3% to $1.27 from $1.70 [3][8] Business Developments - The company announced the retirement of CEO Brian Markison effective December 31, 2025, and is conducting a search for a new CEO [5][7] - Lantheus closed the acquisition of Life Molecular Imaging in July 2025, enhancing its commercial portfolio [7][16] - The company repurchased $100 million of its common stock in Q3 2025 as part of its stock repurchase plan [7][8] Product Sales - Sales of PYLARIFY were $240.6 million, a decrease of 7.4% year-over-year [8][21] - Sales of DEFINITY increased by 6.3% to $81.8 million [8][21] - Operating income decreased by 67.4% to $43.6 million, while adjusted operating income (non-GAAP) fell by 27.6% to $119.6 million [8][21] Cash Flow and Balance Sheet - Free cash flow for Q3 2025 was $94.7 million, down from $159.3 million in Q3 2024 [8][26] - As of September 30, 2025, cash and cash equivalents were $382.0 million, significantly reduced from $912.8 million at the end of 2024 [8][27] Guidance - The updated corporate guidance for full year 2025 revenue is projected to be between $1.49 billion and $1.51 billion [10] - Adjusted fully diluted earnings per share guidance for FY 2025 is set at $5.50 to $5.65 [10]